Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males

Anxiety Clinical Trial

— CXB722-100  

Official title:

A Phase 1, Multiple Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Examining the Effects of CXB722 in Mitigating Neuroendocrine Stress Response in Healthy Males

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00814931
• Other study ID #: AG0114
• Status: Completed
• Phase: Phase 1
• First received: December 23, 2008
• Last updated: January 9, 2009
• Start date: December 2008
• Est. completion date: December 2008

Study information

• Verified date: January 2009
• Source: National Institute on Aging (NIA)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the effects of CXB722 on neuroendocrine stress response and subjective reports related to mood and stress during and after experimentally induced stress among healthy young males.

Description:

Acute stress produces a cascade of physiological and psychological effects, including increased cardiovascular function, increases in circulating levels of stress hormones and neurotransmitter levels, and changes in mood and subjective state. The Trier Social Stress Test (TSST) is a standardized, well-validated procedure that was developed in order to provide a controlled method for exposing subjects to a stressor. The TSST consists of a public speaking and a mental arithmetic test performed in the context of a mock job interview.

A drug that could safely block or mitigate the stress response would have multiple applications in medicine, beyond treating anxiety, because stress is associated with many disease states, including cardiovascular disease. The drug being studied, CXB722, is thought to show promise in diminishing the physiologic and psychological effects of stress.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: December 2008
• Est. primary completion date: December 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 34 Years

Eligibility

Inclusion Criteria:

• Male, 18 to 34 years of age, inclusive, at screening

• Able to read, understand and converse in English

• Able to read, understand, and provide written, dated informed consent

• Willing to refrain from the use of any concomitant medications (including over-the counter (OTC)) and nutritional/herbal supplements and comply with all study requirements

• Willing to submit to daily breathalyzer testing each day study medication is administered over the course of the study

• In good general health as ascertained by medical history, physical examination (PE) including measurement of vital signs, clinical laboratory evaluations, and 12-lead electrocardiogram (ECG)

Exclusion Criteria:

• Evidence on physical examination or laboratory findings of chronic liver or renal disease or other chronic physical disorders

• Evidence of cardiovascular disease on 12 lead ECG, vital signs or laboratory findings

• Significant anxiety as indicated by a score of 47 or higher on the "Trait" score of Spielberger State-Trait Anxiety Scale

• Family history (first degree relative) of hypertension or cardiovascular disease prior to age 40

• Evidence on physical or laboratory examination of endocrinopathies or immunopathies, including HIV

• BMI of 30 or greater, evidence of significant recent weight change or history of obesity

• History of any psychiatric disorder, or evidence of such a disorder based on a psychiatric evaluation which includes the Structured Clinical Interview for DSM-IV-TR (SCID)

• History of any physical condition which, in the investigator's opinion, might put the participant at risk or interfere with the interpretation of study results

• Use of any prescription or over-the-counter (OTC) medications (including herbal remedies) within 14 days of study randomization

• Use of tobacco products or any nicotine-containing products (e.g., gum, patch) within the past 6 months (prior to screening)

• Positive screening urine test for nicotine or drugs of abuse: cannabinoids, cocaine, amphetamines, barbiturates, opiates, benzodiazepines, or alcohol in the blood

• Unwillingness to agree to avoid strenuous activity over the course of the study

• Poor likelihood, in the investigator's judgment, of full cooperation during the study and/or poor compliance is anticipated

• Previously screened for this trial

• Consumes more than four cups of coffee daily

• Deviates from normal nocturnal sleeping patterns

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anxiety
• Stress

Intervention

Drug:
• CXB722
900 mg CXB722 oral liquid suspension twice a day for 8 days
• Placebo
matching oral liquid suspension placebo twice a day for 8 days

Locations

Country	Name	City	State
United States	University of South Florida	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
CeNeRx BioPharma Inc.

Country where clinical trial is conducted

United States, 

References & Publications (2)

Kirschbaum C, Pirke KM, Hellhammer DH. The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology. 1993;28(1-2):76-81. — View Citation

Kirschbaum C, Strasburger CJ, Langkrär J. Attenuated cortisol response to psychological stress but not to CRH or ergometry in young habitual smokers. Pharmacol Biochem Behav. 1993 Mar;44(3):527-31. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma cortisol and salivary cortisol levels		Screening and Study Day 8	No
Secondary	Plasma ACTH		Screening and Study Day 8	No
Secondary	Plasma epinephrine and norepinephrine		Screening and Study Day 8	No
Secondary	Profile of Mood States (POMS) Tension-Anxiety		Screening and Study Day 8	No
Secondary	Fatigue-Inertia, and Vigor-Activity factor scores		Screening and Study Day 8	No
Secondary	"State" score on the Spielberger State-Trait Anxiety Scale (SSTAS)		Screening and Study Day 8	No
Secondary	Seven Visual Analog Scales (VAS)		Screening and Study Day 8	No
Secondary	HR, and systolic and diastolic BP		Screening and Study Day 8	Yes